DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136:1023–32. https://doi.org/10.1182/blood.2019001982

Article  PubMed  PubMed Central  Google Scholar 

Lee KH, Yoon SR, Gong JR, Choi EJ, Kim HS, Park CJ, et al. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial. Leukemia. 2023;37:807–19. https://doi.org/10.1038/s41375-023-01849-5.

Article  CAS  PubMed  Google Scholar 

Yoon S, Lee Y, Yang S, Ahn K, Lee J-H, Lee J-H, et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45:1038–46.

Article  CAS  PubMed  Google Scholar 

Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Jang YJ, et al. Donor-derived natural killer cells infused after human leukocyte antigen–haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20:696–704.

Article  CAS  PubMed  Google Scholar 

Choi I, Yoon SR, Park S-Y, Kim H, Jung S-J, Kang Y-L, et al. Donor-derived natural killer cell infusion after human leukocyte antigen–haploidentical hematopoietic cell transplantation in patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2016;22:2065–76.

Article  CAS  PubMed  Google Scholar 

Lee KH, Lee S, Park YH, Mun YC, Choi EJ, Choi Y, et al. Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis. Leukemia. 2024;38:451–4. https://doi.org/10.1038/s41375-023-02121-6.

Article  CAS  PubMed  Google Scholar 

Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17:700–7.

Article  CAS  PubMed  Google Scholar 

Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, et al. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget. 2017;8:49548–63. https://doi.org/10.18632/oncotarget.17747.

Article  PubMed  PubMed Central  Google Scholar 

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, et al. Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology. 2017;6:e1163456.

Article  PubMed  Google Scholar 

Messaoudene M, Fregni G, Enot D, Jacquelot N, Neves E, Germaud N, et al. NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution. Oncoimmunology. 2016;5:e1154251.

Article  PubMed  PubMed Central  Google Scholar 

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, et al. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology. 2017;6:e1137418.

Article  PubMed  Google Scholar